USPTO 2015–2025 USPTO PatentsView US Corporation

Neodyne Biosciences, Inc.

USPTO PatentsView assignee record - 18 granted patents across 5 technology areas, recorded in grant years 2016–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).

RSS updates for this company

The verdict

According to USPTO PatentsView, Neodyne ranks #16,227 of 49,997 tracked US assignees by granted-patent volume, with 18 patents across 5 technology areas.

#16,227
of 49,997 US assignees by volume
Top 50%
by Innovation Score (35.1/100)
20.9
avg claims per patent
-36%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R16227 · US Corporation #16,227 · 18 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DOWN · BOOK-FULL

  • GRANTS-MICRO 18 grants
  • MID-PACK #16,227/49,997
  • PHOTO-FINISH National Gypsum…
  • CPC-NARROW A61F · 5 areas
  • INNOV-THIN 35.1/100
  • CLAIMS-DENSE 20.9 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DOWN -36% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: National Gypsum Properties, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Neodyne’s 35.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Neodyne

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Neodyne's Innovation Score is 35.1/100 (top 50% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Neodyne?

Each dot is one of Neodyne’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Neodyne’s own 20.9 claims/patent is ABOVE the 20.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Neodyne vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 17.917.91818.1 051015202530 Granted patents (volume) Avg claims / patent National Gypsum Properties, LLC - 18, 19.5National Gypsum P…National University Hospital (Singapore) Pte Ltd - 18, 22National Universi…Nature Technology Corporation - 18, 8.33Nature TechnologyNautilus Subsidiary, Inc. - 18, 25.17Nautilus Subsidia…Netskrt Systems, Inc. - 18, 20.61Netskrt SystemsNeurimmune Holding AG - 18, 25.5Neurimmune HoldingNext Biometrics Group ASA - 18, 21.72Next Biometrics G…Next Level Ventures LLC - 18, 4.78Next Level Ventur…Neodyne Biosciences, Inc. - 18, 20.94Neodyne Bioscienc…
Neodyne vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Neodyne's grants concentrate

Neodyne Biosciences, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 83.3% of grants classified under A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device). Peak complete grant year is 2016 (4 grants) versus a trough of 1 in 2021. By volume, Neodyne sits between National Gypsum Properties, LLC and Next Level Ventures LLC.

Neodyne's three-year grant acceleration

Neodyne Biosciences, Inc. shows 4 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Neodyne's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Neodyne holds 18 patents at rank #16,237, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Neodyne

By rank, the assignees closest to #16,237 in granted patent volume.

Leaders in A61F (Filters Implantable Into Blood Vessels)

Other assignees with the most granted patents in Neodyne's primary technology class.

Neodyne's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

35 Top 50% higher than 50% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

012345 20162017201920202021202220232024 2
USPTO utility patent grants by year · 2016–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table
Neodyne Biosciences, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2016 4 22.2%
2017 4 22.2%
2019 3 16.7%
2020 2 11.1%
2021 1 5.6%
2022 1 5.6%
2023 1 5.6%
2024 2 11.1%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Neodyne Biosciences, Inc.'s patent record in context - here's where to go next.

  • Neodyne Biosciences, Inc.'s lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 83.3% of its portfolio - see every assignee active in that class. Explore A61F
  • Ranked #16,227 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Neodyne Biosciences, Inc. against National Gypsum Properties, LLC, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 35.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.